Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

centurion medical products - lidocaine hydrochloride anhydrous (unii: ec2cnf7xfp) (lidocaine - unii:98pi200987) - lidocaine hydrochloride injection, usp is a sterile, nonpyrogenic solution of lidocaine hydrochloride in water for injection for parenteral administration in various concentrations. multiple dose vials contain 0.1% of methylparaben added as preservative. lidocaine is a local anesthetic of the amide type. the molecular weight is 288.82

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

centurion medical products - lidocaine hydrochloride anhydrous (unii: ec2cnf7xfp) (lidocaine - unii:98pi200987), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride and epinephrine injection, usp is a sterile, nonpyrogenic solution of lidocaine hydrochloride and epinephrine in water for injection for parenteral administration. sodium metabisulfate 0.5 mg/ml and citric acid, anhydrous 0.2 mg/ml added as stabilizers. may contain sodium hydroxide and/or hydrochloric acid to adjust ph; ph is 4.5 (3.3 to 5.5). multiple dose vials contain methylbaraben 1 mg/ml added as preservative. lidocaine is a local anesthetic of the amide type.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bard australia pty ltd - 60776 - surgical adhesive/sealant, microbe-derived - sterile single-use medical device that is formed as a result of mixing two components: (1) a solution of recombinant human albumin (rha), and (2) a synthetic cross-linking component of polyethelyene glycol (peg) that is functionalised with succinate groups. when the two components are mixed together, it makes a 4ml total sealant volume for application on patients undergoing cardiovascular surgery. tridyne? cardiovascular sealant is indicated for use as an adjunct to hemostasis for treatment of cardiovascular and peripheral vasculature focal persistent bleeding by mechanically sealing areas of leakage.

Iisrael - inglise - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Iisrael - inglise - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - dexrazoxane - pdr/conc/soln for infus - 500mg/vial milligram

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - dexrazoxane - pdr/conc/soln for infus - 500mg/vial milligram

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

evalar pty ltd - chromic chloride hexahydrate,crataegus monogyna,folic acid,ubidecarenone,vitis vinifera -

Euroopa Liit - inglise - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - other cardiac preparations - treatment of symptomatic obstructive hypertrophic cardiomyopathy.